Research
Hormonal
The enzyme PTP1B acts as a critical negative regulator of insulin signaling; its absence or inhibition enhances insulin sensitivity and protects against high-fat-diet-induced obesity and insulin resistance.
PTP1B is an enzyme that turns off insulin signals. Inhibiting it improves insulin sensitivity in animal models without obvious negative side effects, making it a promising target for future diabetes treatments.
StrongSupportsHIGH confidence
PTP1B KO mice show enhanced insulin sensitivity, increased IR phosphorylation in muscle and liver, and are also resistant to high-fat-diet-induced obesity and associated insulin resistance.
Why this rating
Supported by knockout mouse studies and extensive citation of foundational work.
Source
Insulin Receptor Signaling in Normal and Insulin-Resistant States
Jérémie Boucher et al. · Cold Spring Harbor Perspectives in Biology · 2014
DOI 10.1101/cshperspect.a009191
narrative_reviewCited 1,452×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Obesity-induced insulin resistance is mechanistically driven by the activation of serine/threonine kinases (such as JNK, IKK, and PKC isoforms) which phosphorylate insulin receptor substrates (IRS) on inhibitory serine residues, thereby blocking normal tyrosine phosphorylation and signal transduction.Strong
- Genetic mutations in the insulin receptor gene cause rare, severe forms of insulin resistance (e.g., leprechaunism), but these mutations are not observed in routine type-2 diabetes.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →